Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $46.26 and last traded at $45.96, with a volume of 381915 shares changing hands. The stock had previously closed at $45.40.
Gemini Therapeutics Trading Up 1.2 %
The company has a market cap of $1.99 billion, a price-to-earnings ratio of -45.96 and a beta of -0.12. The business’s 50 day moving average price is $40.04 and its 200-day moving average price is $48.81.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- There Are Different Types of Stock To Invest In
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Has This Leading Tech Stock Halted the AI Surge?
- What Investors Need to Know to Beat the Market
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
